Physician profile
Peter M Pollak
NPI 1477766509
$15,047.51
in general payments reported to CMS, 2019-2025
5 companies · $6,404 in 2025
The $6,404 reported for 2025 was more than what 86% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $4,209 · 2021: $94.54 · 2022: $975 · 2023: $299 · 2024: $2,730 · 2025: $6,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,880 · Travel and Lodging: $2,850 · Food and Beverage: $1,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,880.00 |
| Travel and Lodging | $2,849.57 |
| Food and Beverage | $1,702.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,445.05 | 2019-2025 | Evoque, Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $5,299.86 | 2021-2025 | Product In Development, Gore Cardioform Septal Occluder |
| Abbott Laboratories | $3,047.65 | 2019-2025 | Triclip, Mitraclip, Amplatzer Amulet |
| Livanova USA, INC. | $129.96 | 2019 | |
| Genzyme Corporation | $124.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pollak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.